KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Titel:
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Auteur:
Swords, Ronan T. Greenberg, Peter L. Wei, Andrew H. Durrant, Simon Advani, Anjali S. Hertzberg, Mark S. Lewis, Ian D. Rivera, Gabriel Gratzinger, Dita Fan, Alice C. Felsher, Dean W. Cortes, Jorge E. Watts, Justin M. Yarranton, Geoff T. Walling, Jackie M. Lancet, Jeffrey E.